for moDC) into professional APC, have better lymph node homing properties and exhibit a more uniform and consistent pro-inflammatory functional status (18) . Here, we evaluated whether activated Vγ9Vδ2-T cells could be used as a novel Ag presenting platform for iNKT cells.
Methods

Antibodies and flow-cytometry
FITC-, PE-, PerCP-or Allophycocyanin (AP)-labeled mAb directed against CD3, CD14, CD1a, CD40, CD80, CD86, CD25 (BD Biosciences, New Jersey, USA), CD83, TCR-Vα24, -Vβ11, -Vδ2, (Beckman Coulter, Inc.), -Vγ9, EpCAM (CD326) (Biolegend, San Diego, USA) and CD1d (clone 51.1; eBiosciences, Inc.) were used for flowcytometry analysis. mAb staining was performed in PBS supplemented with 0.1% BSA and 0.02% sodium-azide for 30 min at 4°C. For intracellular staining of IFN-γ, iNKT cells were harvested after 18 h of co-culture with CD1dor CD1d + Vγ9Vδ2 T cells or α-GalCer pulsed HeLaCD1d cells in the presence of 0.5 µl of Golgi Plug (BD Biosciences), washed and stained with surface membrane mAb. After fixation with Cytofix/Cytoperm solution and permeabilization with Perm/Wash solution (both from BD Biosciences), cells were stained with PE-conjugated mAbs specific for IFN-γ or appropriate isotype control for 30 min at 4°C in permeabilization buffer. Cells were washed with permeabilization buffer and FACS buffer before analysis. All stained cells were analyzed on FACS Calibur (BD Biosciences) using CellQuest software.
Generation of moDC
Immature moDC were generated by allowing PBMC to adhere to culture flasks for 2h at 37 ºC. Adherent cells were cultured for 5-7 days in the presence of recombinant human (rh)IL-4 (10 ng/ml, R&D systems, Minneapolis, USA) and rhGM-CSF (100 ng/ml, Bayer AG, Leverkusen, Germany) in IMDM (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (Hyclone, Amsterdam, The Netherlands), 100 I.E./ml sodium penicillin (Yamanouchi Pharma, Leiderdorp, The Netherlands), 100 μg/ml streptomycin sulphate (Radiumfarma-Fisiopharma, Naples, Italy), 2.0 mM l-glutamine (Invitrogen, Breda, The Netherlands) and 0.05 mM 2-ME (Merck, Darmstadt, Germany), hereafter referred to as complete medium. Immature moDC were matured with 100 ng/ml LPS (SIGMA, St. Louis, Missouri, USA) during 24-48h at 37°C in a humidified atmosphere under 5% CO 2 . Mature moDC were harvested by 5 mM ethylenediaminetetraacetic acid (EDTA) 6 in phosphate buffered saline (PBS, Braun Melsungen AG, Melsungen, Germany) and used for co-culturing experiments, or irradiated (5000 Rad) and used for weekly stimulation of purified cells.
Generation of Vγ9Vδ2-T cell lines and Vγ9Vδ2-T APC
Vγ9Vδ2-T cell lines were generated from human PBMC by magnetic activated cell sorting (MACS) using either the murine anti-human Vδ2 TCR or anti-human Vγ9 TCR mAb, combined with a polyclonal Goat-anti-Mouse Ab or anti-PE Ab labelled with magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). For culture/expansion of Vγ9Vδ2-T cells, 100 μM of the NBP Pamidronate (PCH, Pharmachemie BV, Haarlem, The Netherlands) was added to immature moDC during the last 2h of maturation with LPS and co-cultured with Vγ9Vδ2-T cells with rhIL-2 (50 U/ml, BioVision, Mountain View, California, USA). Purified Vγ9Vδ2-T cells were weekly re-stimulated with irradiated feeder-mix consisting of allogeneic PBMC and Epstein Barr Virus (EBV)-transformed B cells in Yssel's medium supplemented with 50 ng/ml PHA (Murex Biotech, Dartford, U.K.) and 50 U/ml IL-2. Purity of Vγ9Vδ2-T cells used for experiments was >90%.
In experiments in which the acquisition of APC marker expression and function of Vγ9Vδ2-T was studied, both resting and activated freshly isolated Vγ9Vδ2-T cells and V9V2-T cell lines were used. Activated Vγ9Vδ2-T cells were obtained using either soluble anti-CD28 (2 μg/ml) mAb and PHA (3 μg/ml) stimulation, or following co-culture with EBV-B cells that were pre-treated overnight with 100 μM NBP as indicated (ratio 1:1; both in co-culture and in a transwell setting (0.4 μm pore size, Costar, Corning Incorporated)). After 48-72h Vγ9Vδ2-T were harvested (where required after MACS purification) and either analyzed on FACS or used for co-culture assays.
Generation of iNKT cell lines and iNKT activation experiments
For iNKT (defined as Vα24 + Vβ11 + ) cell expansion experiments iNKT cells were isolated from PBMC through MACS-isolation using the 6B11 mAb (kind gift of Mark Exley, BIDMC, Harvard Medical School, Boston), or the murine anti-human TCR Vα24-chain mAb, combined with a polyclonal Goat-anti-Mouse Ab labelled with magnetic beads (Miltenyi Biotec). iNKT cells were expanded by co-culturing iNKT with moDC, pulsed with α-GalCer (100 ng/ml, Funakoshi Co, Tokyo, Japan) during maturation, and rhIL-2 (50 U/ml). Purified iNKT cells were re-stimulated weekly with irradiated feeder-mix consisting of allogeneic PBMC and EBVtransformed B cells in Yssel's medium supplemented with 50 ng/ml PHA and 50 U/ml IL-2. Purity of iNKT cells used for experiments was >90%.
For evaluation of iNKT cell activation, different APC (HeLa-CD1d, moDC, freshly isolated Vγ9Vδ2-T cells, Vγ9Vδ2-T cell lines and sorted Vγ9Vδ2-T APC) were pre-treated with 100 ng/ml α-GalCer or vehicle control during 24h at 37°C in a humidified atmosphere under 5% CO 2. FACS SORT (BD FACSAria) was performed based on TCR-Vδ2 (FITC or PerCP) and TCR-Vγ9 (PE or AP) double positive selection. Cell doublets were excluded using a doublet excluding gate, based on the linear correlation between height and area of a cell. Post SORT all conditions consisted of a >95% pure Vγ9Vδ2-T cell population. After α-GalCer pre-treatment, the different APC were washed thoroughly to lose all excessive α-GalCer and co-cultured with resting iNKT cells (ratio 1:1). After 18-24h, supernatants were harvested and analyzed using the Th1/Th2/Th17 BD™ Cytometric Bead Array kit (CBA; BD Biosciences) for the simultaneous flow cytometric detection of IL-2, IL-4, IL-5, IL-10, TNF-α, and IFN-γ, following the manufacturer's instructions and with the use of CBA analysis software (BD Biosciences), and cells were used for flow cytometric analysis of CD25 expression or intracellular IFN-γ production.
Membrane exchange experiments.
EBV-transformed B cells, cultured overnight in the presence or absence of 100 μM NBP, were suspended in PBS, labeled for 10 min with 1 μM of the cell permeable, non-fluorescent pro-dye CFSE (Molecular Probes/ Invitrogen) at 37°C, and washed thoroughly with complete medium to be subsequently labeled with the fluorescent membrane dye PKH26 (Sigma, Missouri, USA) according to the manufacturers' guidelines. Vγ9Vδ2-T cells were stained with the fluorescent membrane dye Cellvue according to the manufacturers' guidelines. CFSE/PKH26 labeled EBV-B and Cellvue labeled Vγ9Vδ2-T cells were co-cultured (ratio 1:1) for up to 24h at 37°C in a humidified atmosphere under 5% CO 2 . Membrane exchange was determined by assessing the amount of PKH26 that was acquired by Vγ9Vδ2-T cells at various time-points during this co-culture using flow-cytometry.
In order to determine transfer of CD1d molecules, HeLa or CD1dtransfected HeLa cells, pre-treated for 2h with 100 μM NBP, were co-cultured with Vγ9Vδ2-T cells. At various time-points the activation status and CD1d expression of Vγ9Vδ2-T cells was determined. To evaluate whether transfer of CD1d resulted from membrane exchange or transfer of exosomes, CD1dtransfected HeLa cells were pre-treated for 1h with either the exosome transport inhibitor Manumycin A (9 μM; Sigma) or NaN 3 (10 mM), which depletes cellular ATP, in the presence or absence of 100 μM NBP. Vγ9Vδ2-T cells, pre-treated for 1h with the actin filament inhibitor Cytochalasin B (10 μM; Sigma) were used to study the role of actin dependent uptake of membrane fragments. After 6 washing, pre-treated Vγ9Vδ2-T cells and NBP pre-treated CD1d-transfected HeLa cells were co-cultured (ratio 1:1) for flow-cytometric assessment of Vγ9Vδ2-T cell CD1d expression at various time points.
ImageStream analysis
CD1d transfected HeLa cells, pre-treated with 100 μM NBP, were overnight cocultured with Vγ9Vδ2-T cells, harvested and used for analyses. Anti-TCR-Vδ2 mAb (FITC labeled) was used to identify Vγ9Vδ2-T cells; anti-CD1d mAb (APC labeled) was used for determining CD1d acquisition by Vγ9Vδ2-T cells. Images were collected using an ImageStream ISX imaging flow-cytometer (Amnis Corporation). A total of 10.000-30.000 events of cell images were collected. IDEAS Image Analysis Software (Amnis Corporation) was used for data analysis.
Statistical analysis
All data were analysed using paired Student T-tests, 1-way ANOVA or Mann Whitney tests, as appropriate; P≤0.05 was considered statistically significant.
Results
α-Galactosylceramide-pulsed pAg-activated Vγ9Vδ2-T cells do not trigger iNKT cell activation
In order to evaluate the APC capacity of V9V2-T cells, we used NBP pre-treated (pAg positive) EBV-transformed B cells (pAg + EBV-B) to generate Vγ9Vδ2-T APC according to the protocol described by Brandes et al. (16) . The generated Vγ9Vδ2-T APC were pulsed with α-GalCer and used to study iNKT cell activation, where α-GalCer-pulsed CD1d-transfected HeLa cells served as a positive control. Notably, after 24h of co-culture, α-GalCer-pulsed Vγ9Vδ2-T APC were not able to activate iNKT cells (as measured by the upregulation of the activation marker CD25), irrespective of whether Vγ9Vδ2-T APC were derived from freshly isolated Vγ9Vδ2-T cells or from Vγ9Vδ2-T cell lines and irrespective of the mode of activation that was used ( Fig. 1 and data not shown). Phenotypical analysis of Vγ9Vδ2-T APC revealed that co-culture of pAg + EBV-B cells with Vγ9Vδ2-T lead to appropriate pAg-induced Vγ9Vδ2-T activation and that activated Vγ9Vδ2-T cells expressed higher levels of the co-stimulatory molecules CD86 and CD40, comparable to activated APC. However, no CD1d expression could be detected on either the resting or activated Vγ9Vδ2-T APC (Fig. 2 ). Although an earlier report indicated that pAg-induced activation of Vγ9Vδ2-T cells was sufficient to induce APC characteristics in V9Vδ2-T cells, a contribution by additional factors provided by pAg + B-cells was not formally excluded (16) . Based on the hypothesis that the pAg + stimulatory cell could be involved in transferring APC characteristics, we considered that although EBV-B cells are known to be well capable of presenting Ag via MHC class I and II, their CD1d-restricted Ag presenting capacities are compromised as EBV-B cells in vitro often down-regulate CD1d expression on their cell surface and are thus relatively poor in presenting α-GalCer to iNKT cells (19, 20) .
Phosphoantigen dependent uptake of lipophilic membrane dye and CD1d molecules by Vγ9Vδ2-T cells
Interestingly, when cultures of pAg + EBV-B cells and Vγ9Vδ2-T cells were analysed by flow-cytometry, a small but distinct population of TCR-Vδ2 + -T cells also expressing the B-cell antigen CD19 could be observed (Fig. 3A ). Within this CD19 expressing Vδ2-T cell population a CD19 bright subset, possibly representing cell doublets, and a CD19 dim population was observed, possibly representing Vγ9Vδ2-T cells that had acquired CD19 containing (i.e. EBV-B cell derived) membrane patches. In order to evaluate whether membrane exchange between Vγ9Vδ2-T and EBV-B cells occurred, EBV-B cells were pre-treated with 0 or 100 µM NBP and stained with a combination of the protein dye CFSE and the membrane dye PKH26 while the Vγ9Vδ2-T cells were stained with the membrane dye Cellvue. CFSE/PKH26-labeled EBV-B cells and Cellvue-labeled Vγ9Vδ2-T cells were subsequently co-cultured. Indeed during this co-culture we observed an exchange of the lipophilic membrane dye PKH26 from the EBV-B cells to the Vγ9Vδ2-T cells. Notably, this process was pAg-specific and time-dependent (Fig.  3B) .
In further experiments designed to study the functional relevance of the observed membrane exchange, CD1d-transfected HeLa cells were used as these cells constitute a well-established model for studying iNKT cell activation. Co-culture of Vγ9Vδ2-T cells with pAg + HeLa or pAg + HeLa-CD1d cells resulted in comparable activation of V9Vδ2-T cells (Vγ9Vδ2-T cell CD25 expression 90.3% ± 4.6% (mean ± SEM) for pAg + HeLa cells and 87.6% ± 4.2% for pAg + HeLa-CD1d cells; p=0.37, n=7, data not shown). Only the co-culture of Vγ9Vδ2-T with pAg + HeLa-CD1d cells lead to the acquisition of CD1d molecules by Vγ9Vδ2-T cells (mean 36.4% ± 5.5%). In a co-culture with untreated HeLa-CD1d cells there was minimal acquisition of CD1d by Vγ9Vδ2-T cells (mean 4.9% ± 1.7%), compared to the expression of CD1d on Vγ9Vδ2-T cells after co-culture with pAg + HeLa cells (mean 0.4% ± 0.4%), indicating the pAg-specific contact dependent transfer of CD1d molecules from HeLa-CD1d to Vγ9Vδ2-T cells (Fig. 3C ). The acquisition of CD1d by Vγ9Vδ2-T cells was both pAg-concentration dependent and time-dependent with an optimum between 7-21h (7h mean 33.1% ± 6.3%; 21h mean 24.8% ± 4.3%; n=4; 0μM vs 100 μM p=0.01; data not shown). Similar levels of CD1d were acquired using effector to target ratios of 1:1 or 1:10. Furthermore, acquisition of CD1d by Vγ9Vδ2-T cells was also observed after pre-treating HeLa-CD1d cells with the agonist anti-CD277 mAb (clone 20.1) which mimics pAg-stimulation of Vγ9Vδ2-T cells (data not shown). Of note, transfer of CD1d molecules from donor cells to Vγ9Vδ2-T cells was not restricted to HeLa-CD1d cells as it was also observed using other CD1d-expressing donor cells, including CD1d-transfected C1R cells.
Possible explanations for the transfer of membrane molecules between cells include exosomal transfer and trogocytosis. Trogocytosis is the process whereby lymphocytes intimately interact with other cells to extract surface molecules from these cells and present them on their own surface (21). The formation of an immune synapse through cell surface ligand/receptor interaction enables the rapid transfer of immune-modulatory surface proteins contained in a membrane patch, a process referred to as synaptic transfer (22, 23) . In order to evaluate whether membrane transfer between HeLa-CD1d and Vγ9Vδ2-T cells results from either trogocytosis or transfer of exosomes, a separate set of experiments was performed in which either Vγ9Vδ2-T cells were pre-treated with an inhibitor of actin polymerization, Cytochalasin B (blocking trogocytosis) or the pAg + HeLa-CD1d cells were pre-treated with Manumycin A or the cytochrome oxidase inhibitor NaN 3 (blocking exosome transport/release) before co-culture of Vγ9Vδ2-T and HeLa-CD1d cells. As shown in Fig. 3D , pre-treatment of pAg + HeLa-CD1d cells with neither Manumycin A nor NaN 3 decreased the acquisition of CD1d by Vγ9Vδ2-T cells at various time points (up to 6h tested) after Vγ9Vδ2-TCR engagement, implicating that an active role of the CD1dexpressing donor cell is not required for the observed membrane exchange, and that this is therefore not mediated by transfer of exosomes. In contrast, administration of the actin-filament inhibitor Cytochalasin B did significantly decrease acquisition of CD1d by Vγ9Vδ2-T cells without affecting Vγ9Vδ2-T cell activation as determined using CD25 expression (data not shown), suggesting an active role of this pathway in Vγ9Vδ2-T cell membrane exchange (p<0.01; n=5).
We then quantified membrane exchange using the ImageStream. This instrument combines microscopy and flow cytometry in one platform. Because it images cells in flow, the system -on a per cell basis -is able to measure the brightness, size and location of subcellular components (labeled with fluorochrome conjugated antibodies) and compile this data into the population statistics of conventional FACS analysis. Hence, after an overnight co-culture of Vγ9Vδ2-T cells with either HeLa-CD1d or pAg + HeLa-CD1d, Vγ9Vδ2-T cells were analyzed for the expression of CD1d. As observed in previous experiments, most Vγ9Vδ2-T cells co-cultured with HeLa-CD1d expressed no or very low levels of CD1d. However, in a co-culture with pAg + HeLa-CD1d cells, substantially more Vγ9Vδ2-T cells obtained CD1d expression, which could be visualized as trogocytosed CD1d-containing patches on the membrane of Vγ9Vδ2-T cells ( Fig. 4A and 4B ). Therefore, both Vγ9Vδ2-T cells co-cultured with pAg + and pAg -HeLa-CD1d can acquire CD1d, as is also reflected in Fig. 3C . However, when quantified as a function of area and intensity, the CD1d staining on the plasma membrane of the Vγ9Vδ2-T cells cultured with pAg + HeLa-CD1d was larger and brighter than the CD1d staining on the plasma membrane of Vγ9Vδ2-T cells cultured with HeLa-CD1d (approximately 2-fold increase; data not shown) and the percentage of Vγ9Vδ2-T cells that acquire CD1d after coculture with pAg + and pAg -HeLa-CD1d cells differs greatly (Fig. 4B) . Thus by two different criteria, the ImageStream data indicate a greater abundance of CD1d on the membrane of Vγ9Vδ2-T cells cultured with pAg + HeLa-CD1d compared to Vγ9Vδ2-T cells cultured with untreated HeLa-CD1d. Polarization of the TCR (Vδ2) was frequently observed at the site of CD1d positive membrane uptake ( Fig. 4A and 4B) , suggesting that the observed trogocytosis took place at an immunological synapse, as described previously for trogocytosis (21-23). However, when quantified as a function of area and intensity, the CD1d staining on the plasma membrane of the Vγ9Vδ2-T cells cultured with pAg + HeLa-CD1d was larger and brighter than the CD1d staining on the plasma membrane of Vγ9Vδ2-T cells cultured with HeLa-CD1d (approximately 2-fold increase; data not shown) and the percentage of Vγ9Vδ2-T cells that acquire CD1d after coculture with pAg + and pAg -HeLa-CD1d cells differs greatly (Fig. 4B) . Thus by two different criteria, the ImageStream data indicate a greater abundance of CD1d on the membrane of Vγ9Vδ2-T cells cultured with pAg + HeLa-CD1d compared to Vγ9Vδ2-T cells cultured with untreated HeLa-CD1d. Polarization of the TCR (Vδ2) was frequently observed at the site of CD1d positive membrane uptake ( Fig. 4A and 4B ), suggesting that the observed trogocytosis took place at an immunological synapse, as described previously for trogocytosis (21-23).
Trogocytosis of CD1d-containing membrane fragments endows Vγ9Vδ2-T cells with the capacity to act as APC for iNKT
Next, the iNKT cell activating capability of V9V2-T APC was evaluated after their trogocytosis-mediated acquisition of CD1d. For this purpose, CD1d + and CD1d -Vγ9Vδ2-T cells, purified from co-cultures with α-GalCer-pulsed pAg + HeLa-CD1d cells and α-GalCer-pulsed pAg + HeLa cells respectively, were co-cultured with resting iNKT cells for 24h. Purification of Vγ9Vδ2-T cells was performed by FACS sort using a doublet excluding gate (based on the linear correlation between area and height of cells). After co-culturing CD1d-expressing Vγ9Vδ2-T APC and iNKT for 24h, iNKT cell activation was determined by CD25 expression, while cytokine production (IL-2, IL-4, IL-6, IL-10, TNF-, IFN-γ, IL-17) was determined using an inflammatory Cytometric Bead Array (CBA). As mentioned earlier, Vγ9Vδ2-T cells were equally activated in both conditions, implying that observed differences resulted from differences in iNKT cell cytokine production.
α-GalCer-loaded CD1d + sorted Vγ9Vδ2-T APC significantly increased iNKT cell activation when compared to CD1d -Vγ9Vδ2-T APC (iNKT/CD1d -Vγ9Vδ2-T cell co-culture vs iNKT/CD1d + Vγ9Vδ2-T cell co-culture for percent CD25 + iNKT cells: 31.7 ± 5.4 vs 38.0 ± 6.2 (means ± SEM p=0.007; n=13); for MFI 66.0 ± 8.2 vs 75.6 ± 6.7 (means ± SEM p=0.046, n=13) ( Fig 5A) . More prominently, α-GalCerloaded CD1d + sorted Vγ9Vδ2-T also stimulated iNKT cells to produce increased levels of IFN-γ (iNKT/CD1d -Vγ9Vδ2-T cell co-culture mean 2173 ± 780 pg/ml v iNKT/CD1d + Vγ9Vδ2-T cell co-culture mean 4070 ± 671 pg/ml, p=0.004; n=7) (Fig.  5B) , which was also confirmed by intracellular IFN-γ detection (mean ± SD iNKT cell IFN-γ expression 0.9 ± 0.4% using CD1d -Vγ9Vδ2-T APC vs 11.1 ± 1.8% using CD1d + Vγ9Vδ2-T APC (n=2) (Fig. 5C ), thereby showing their ability to propagate 6 a Th1-biased immune response. However, the production of IFN-γ by iNKT cells that were stimulated by α-GalCer-pulsed moDC was clearly higher (mean 29789 ± 10636 pg/ml) (Fig. 5B ). For the other cytokines (IL-2, IL-4, IL-6, IL-10, IL-17) no significant differences between CD1d + and CD1d -Vγ9Vδ2-T APC (IL-2 p=0.22; IL-4 p=0.18; IL-6 p=0.62; IL-10 p=0.39; IL-17 p=0.72; data not shown) were detected, with the exception of a small but significant increase in TNF-α (iNKT/CD1d -Vγ9Vδ2-T cell co-culture mean 8 ± 3 pg/ml v iNKT/CD1d + Vγ9Vδ2-T cell co-culture mean 12 ± 3 pg/ml, n= 7; p=0.03; data not shown), in keeping with a Th1-skewed response. Again, the production of TNF-α by iNKT was higher when iNKT were stimulated by α-GalCer-pulsed moDC (mean 1192 ± 739). Interestingly, however, type-2 cytokines, like IL-4 and IL-10 were hardly produced in a co-culture of iNKT/CD1d + Vγ9Vδ2-T cells, in contrast to the co-culture of iNKT/moDC ( Fig 5B) . When considering IFN-γ/IL-4 ratios a trend towards a more type 1-skewed response is induced by Vγ9Vδ2-T APC compared to moDC (IFN-γ/IL4 ratio iNKT/ CD1d + Vγ9Vδ2-T cell 687 ± 285 vs co-culture of iNKT/moDC 257 ± 84; n=7; p= 0.14; data not shown).
Discussion
iNKT cells represent a conserved immunoregulatory T-cell subset with a wellestablished role in anti-tumor immunity based on their capacity to induce long-lasting Th1-biased pro-inflammatory immune responses upon activation (5, 24, 25) . Since preclinical data indicated that i.v. administration of α-GalCerpulsed DC exerted greater antitumor activity compared to i.v. α-GalCer alone (26) , This approach, with variations in the employed APC platform, was subsequently evaluated in clinical trials. Of interest, clinical trials with α-GalCer-pulsed moDC have shown anecdotal antitumor activity in advanced cancer (6, 7) . Figure 5 . CD1d expressing Vγ9Vδ2-T cells can act as APC to activate iNKT. Vγ9Vδ2-T cells co-cultured with glycolipid-Ag pulsed pAg+HeLa or glycolipid-Ag pulsed pAg+HeLa-CD1d cells were purified using flow-cytometric sorting and subsequently co-cultured with iNKT cells (ratio 1:1). After a 24h co-culture iNKT cell CD25 expression was assessed by flow-cytometry and supernatants were harvested and analyzed using a Th1/Th2/Th17 CBA kit. A) Shown are means of CD25 expression (iNKT/CD1d-Vγ9Vδ2-T cell co-culture vs iNKT/CD1d+Vγ9Vδ2-T cell co-culture p=0.007;n=13). B) Shown are means of IFN-γ (iNKT/ CD1d-Vγ9Vδ2-T cell co-culture vs iNKT/CD1d+Vγ9Vδ2-T cell co-culture p=0.004; n=7), IL-4 (iNKT/CD1d-Vγ9Vδ2-T cell co-culture vs iNKT/CD1d+Vγ9Vδ2-T cell co-culture p=0.18; n=7), and IL-10 production (iNKT/CD1d-Vγ9Vδ2-T cell co-culture vs iNKT/CD1d+Vγ9Vδ2-T cell co-culture p=0.39; n=7). Also, means of IFN-γ, IL-4 and IL-10 production by iNKT stimulated by moDC are shown (n=7). C) Dot plots showing increased intracellular IFN-γ expression in iNKT cells cultured for 18 h with CD1d+Vγ9Vδ2-T cells compared to CD1d-Vγ9Vδ2-T cells. Representative data from one of two experiments are shown. 6 There are several practical limitations that hamper further clinical exploration of treatment with α-GalCer-pulsed DC. In general, DC used for clinical trials are derived from monocytes that are differentiated and matured into mature moDC during an in vitro culture period of up to 10 days using combinations of IL-4, GM-CSF and a maturation stimulus. MoDC can acquire different states of function, including tolerogenic (immature DC), pro-inflammatory (mature DC), and inhibitory (mature exhausted DC) (18) . The combination of a relatively long in vitro culturing period and functional heterogeneity, hampers broad clinical application and could cause unfavourable effects (18) . Therefore, alternative APC platforms are the focus of investigation.
Vγ9Vδ2-T cells have been shown to be able to acquire professional Ag presenting capacities, including the uptake and processing of exogenous antigen, and the subsequent presentation of peptide-Ag to CD4 + and CD8 + T cells (via MHC class II and class I respectively) upon their activation by pAg (16, 17) . When compared to moDC, the use of Vγ9Vδ2-T-APC could provide advantages with respect to clinical application (antitumor immunotherapy), since Vγ9Vδ2-T cells are more numerous compared to DC-precursors and can be matured into consistent pro-inflammatory APC within 24h using pAg (16, 18) . We therefore evaluated whether Vγ9Vδ2-T APC might constitute an attractive alternative APC platform for glycolipid Ag presentation to iNKT cells.
Here, we confirmed previous studies demonstrating that activation of Vγ9Vδ2-T cells results in an upregulation of co-stimulatory molecules and APC maturation markers. Activated Vγ9Vδ2-T cells were, however, not able to activate iNKT cells when pulsed with α-GalCer. Importantly, Vγ9Vδ2-T APC generated using previously reported culture systems were found not to express CD1d molecules. Using an alternative platform for generation of Vγ9Vδ2-T APC, CD1d expression was induced on the cell surface of Vγ9Vδ2-T cells. Yet, this expression did not result from de novo synthesis of CD1d, but was critically dependent on the expression of CD1d on the pAg + cells that were used for activation of Vγ9Vδ2-T cells. Using a variety of techniques, we show that the presence of CD1d antigen presenting molecules on the surface of activated Vγ9Vδ2-T cells was mediated by transfer of CD1d molecules from CD1d-positive NBP pre-treated cells that were used for stimulation of Vγ9Vδ2-T APC. Notably, this acquisition of CD1d occurred in a pAg-specific and time-dependent manner, which is typical for trogocytosis and occurs rapidly after TCR engagement. Membrane transfer was not mediated by exosome transport, since the well-established exosometransport inhibitor Manumycin A and the ATP synthase inhibitor NaN 3 did not diminish the acquisition of CD1d by Vγ9Vδ2-T cells triggered in the first few hours after TCR engagement. In contrast, the actin filament inhibitor, Cytochalasin B, decreased the acquisition of CD1d by activated Vγ9Vδ2-T cells, suggesting that actin cytoskeleton rearrangement processes contribute to the observed exchange of membrane fragments. Polarization of the TCR (Vδ2) at the site of CD1d positive membrane exchange suggests that trogocytosis took place at the immunological synapse, as reported previously (22, 23) .
Upon activation, Vγ9Vδ2-T cells can potentially lyse the pAg + HeLa-CD1d cells used for their stimulation. To study the potential contribution of phagocytosis (27) of HeLa-CD1d cell fragments by Vγ9Vδ2-T APC we analyzed whether CD1d expression levels could be enhanced when (EpCAM expressing) HeLa-CD1d cells were coated with anti-EpCAM antibodies. Importantly, antibodycoating of HeLa-CD1d cells did not result in an enhancement of CD1d expression by Vγ9Vδ2-T cells, implicating a limited/absent role for phagocytosis in our experimental system, possibly related to the low CD16 (FcγRIIIa/b) expression levels on Vγ9Vδ2-T cells used in our study (data not shown).
Importantly, glycolipid-loaded CD1d + Vγ9Vδ2-T APC were found to be able to selectively activate and induce IFN-γ, and less prominently TNFαproduction in iNKT cells, indicative of Th1-skewing. While glycolipid loaded moDC outperformed Vγ9Vδ2-T APC on a per cell basis, and induced higher iNKT cell proliferation as compared to CD1d + Vγ9Vδ2-T cells in preliminary experiments (data not shown), Vγ9Vδ2-T APC possess several uniquely favourable features with respect to clinical immunotherapeutic application, as Vγ9Vδ2-T cells are more numerous compared to DC precursors, mature quickly into professional APC, have better lymph node homing characteristics and a more consistent pro-inflammatory phenotype (16, 18) . These characteristics make them an interesting platform for further consideration in future clinical trials. In addition, the more limited iNKT cell activating properties of Vγ9Vδ2-T APC could also be advantageous as they might result in the diminished induction of iNKT cell anergy, which was a limiting factor in earlier studies (28) . Apart from their role as APC, Vγ9Vδ2-T cells have well-established direct anti-tumor effector functions, leading to tumor cytotoxicity via the secretion of perforin, granzyme B and granulysin. In addition to their direct anti-tumor effects, locally activated Vγ9Vδ2-T cells, could also play a role in influencing the development of a Th1biased anti-tumor response in the tumor microenvironment by acting as APC via trogocytosis of tumor derived immunogenic membrane fragments. Our current findings about the role of trogocytosis in the acquisition of CD1d-restricted Ag presentation characteristics fuel the hypothesis that although de novo synthesis of APC molecules was implicated for MHC type I and II molecules, trogocytosis 6 can certainly contribute.
To achieve a more effective APC platform for iNKT cell-based immunotherapy one could envision using retroviral CD1d transduction of Vγ9Vδ2-T cells, hypothesizing that the limited CD1d restricted APC function of Vγ9Vδ2-T cells could be related to the relatively limited surface density of CD1d when compared to HeLa-CD1d or moDC. Furthermore, since repeated i.v. administration of α-GalCer induces iNKT cell anergy and repeated administration of CD1d-targeted constructs results in sustained iNKT cell activation (29) , tumor targeting of iNKT cells or α-GalCer pulsed APC might alternatively constitute a powerful yet unexplored clinical approach (5) .
Our findings provide evidence that Vγ9Vδ2-T cells can acquire the capacity to act as APC and present glycolipid Ag to iNKT cells. However, we show that this does not result from the de novo synthesis of CD1d glycolipid Ag presenting molecules by Vγ9Vδ2-T cells, but critically depends on the uptake of CD1d containing membrane fragments from pAg + target cells with which they interact.
